Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 16,293 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: double-blind placebo Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Effects Of Detrol LA On Memory And Cognition In Elderly Population

NCT00411437
View directory record Official record
Conditions
Memory, Cognition
Interventions
Tolterodine ER, Oxybutynin ER
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
65 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tucson, Arizona • Brooksville, Florida • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort

NCT07163637
View directory record Official record
Conditions
Healthy Participants, Upper Gastrointestinal Discomfort
Interventions
Limosilactobacillus reuteri DSM 17648, Placebo
Dietary Supplement
Lead sponsor
Novozymes A/S
Industry
Eligibility
30 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 22, 2026, 2:15 AM EDT
Recruiting Phase 3 Interventional

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C)
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
44
States / cities
Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Relief 24_RLN: A Study Assessing the Impact of Health and Wellness Products on Pain and Related Health Outcomes.

NCT07160712
View directory record Official record
Conditions
Pain
Interventions
Relief Product Placebo Control, Relief Active Product 1, Relief Active Product 2, Relief Active Product 3
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination

NCT04951336
View directory record Official record
Conditions
COVID-19 Vaccination
Interventions
FoTv
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 22, 2026, 2:15 AM EDT
Withdrawn Phase 1 Interventional

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

NCT00487799
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Ularitide
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

NCT01399684
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 22, 2026, 2:15 AM EDT
Terminated Phase 2 Interventional Results available

Dysport in Vulvodynia Phase II Study

NCT03598777
View directory record Official record
Conditions
Vulvodynia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Miami, Florida • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

NCT05196919
View directory record Official record
Conditions
Facet Joint Pain, Back Pain, Inflammation
Interventions
XT-150, Placebo
Biological
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Napa, California • Santa Monica, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 22, 2026, 2:15 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

NCT01069965
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD
Drug
Lead sponsor
N-Gene Research Laboratories, Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • Paramount, California • Tustin, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance

NCT05703009
View directory record Official record
Conditions
Fructan Intolerance
Interventions
Sacrosidase Oral Solution, Placebo
Drug
Lead sponsor
QOL Medical, LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT02100514
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
108
States / cities
Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)

NCT02155829
View directory record Official record
Conditions
PTSD
Interventions
Riluzole, Placebo (for Riluzole)
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

NCT04435431
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mesdopetam, Placebo
Drug
Lead sponsor
Integrative Research Laboratories AB
Industry
Eligibility
30 Years to 79 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • Long Beach, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 22, 2026, 2:15 AM EDT
Recruiting Phase 3 Interventional

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
NTLA-2001, Placebo
Biological · Drug
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
38
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

NCT03353753
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
DCC-2618, Placebo Oral Tablet
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 22, 2026, 2:15 AM EDT
Terminated Phase 2 Interventional

DNS-7801 vs. Placebo in Parkinson's Disease

NCT03306329
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
30 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 22, 2026, 2:15 AM EDT
Recruiting Phase 2 Interventional

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

NCT05604131
View directory record Official record
Conditions
Acute Myocardial Infarction Type 1
Interventions
Deferiprone Tablets, Placebo
Drug
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

NCT04756531
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07321332 Dose 1, PF-07321332 Dose 2, PF-07321332 Dose 3, PF-07321332 Dose 4, PF-07321332 Dose 5, PF-07321332 Dose 4 or Placebo (Fed)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

NCT02856802
View directory record Official record
Conditions
Migraine Headaches
Interventions
Sumatriptan 10 mg Nasal Spray, Sumatriptan Placebo Nasal Spray
Drug · Other
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
San Diego, California • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

JBT-101 in Systemic Lupus Erythematosus (SLE)

NCT03093402
View directory record Official record
Conditions
Systemic Lupus Erythematosus, SLE, Lupus
Interventions
JBT-101, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 2:15 AM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
125
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Results available

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

NCT01316302
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Pristiq, Placebo
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 22, 2026, 2:15 AM EDT